Soft-tissue extramedullary multiple myeloma prognosis is
significantly worse in comparison to bone-related
extramedullary relapse

J 2014

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

POUR, Luděk; Sabina ŠEVČÍKOVÁ; Henrieta GREŠLIKOVÁ; Renata KUPSKÁ; Petra MÁJKOVÁ et al.

Základní údaje

Originální název

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

Autoři

POUR, Luděk; Sabina ŠEVČÍKOVÁ; Henrieta GREŠLIKOVÁ; Renata KUPSKÁ; Petra MÁJKOVÁ; Lenka ZAHRADOVÁ; Viera SANDECKÁ; Zdeněk ADAM; Marta KREJČÍ; Petr KUGLÍK a Roman HÁJEK

Vydání

Haematologica/the hematology journal, Fondazione Ferrata Storti, 2014, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.814

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00075357

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

alpha interferon; bortezomib; lenalidomide; melphalan; thalidomide

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 7. 2014 14:51, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analyzed the prognosis of 226 relapsed multiple myeloma patients treated between 2005 and 2008 and evaluated them for presence of extramedullary relapse. We found evidence of extramedullary relapse in 24% (55 of 226) of relapsed multiple myeloma patients. In 14% (32 of 226) of patients, the lesions were not adjacent to the bone, while extramedullary relapse adjacent to the bone was documented in 10% (23 of 226) of cases. Patients without extramedullary relapse had significantly longer overall survival than patients with extramedullary relapse (109 vs. 38 months; P<0.001). Moreover, patients with soft tissue-related extramedullary relapse had significantly poorer overall survival compared to bone-related extramedullary relapse patients (30 vs. 45 months; P=0.022). Also, overall survival from diagnosis was as low as five months for soft tissue-related extramedullary relapse patients when compared to 12 months overall survival for bone-related extramedullary relapse. This is the first study that shows a significant difference in prognosis for different types of extramedullary relapse. If the extramedullary myeloma infiltration was not bone-related, overall survival after relapse was extremely short (5 months).

Návaznosti

MSM0021622434, záměr

Název: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

MUNI/11/InGA17/2012, interní kód MU

Název: MikroRNA v patogenezi extramedulárního relapsu mnohočetného myelomu

Investor: Masarykova univerzita, MikroRNA v patogenezi extramedulárního relapsu mnohočetného myelomu

NT11154, projekt VaV

Název: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu

Investor: Ministerstvo zdravotnictví ČR, Úloha mitotické disrupce v B lymfocytech u mnohočetného myelomu

Citovat

POUR, Luděk; Sabina ŠEVČÍKOVÁ; Henrieta GREŠLIKOVÁ; Renata KUPSKÁ; Petra MÁJKOVÁ; Lenka ZAHRADOVÁ; Viera SANDECKÁ; Zdeněk ADAM; Marta KREJČÍ; Petr KUGLÍK a Roman HÁJEK. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica/the hematology journal. Fondazione Ferrata Storti, 2014, roč. 99, č. 2, s. 360-364. ISSN 0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2013.094409.

@article{1180892,
   author = {Pour, Luděk and Ševčíková, Sabina and Grešliková, Henrieta and Kupská, Renata and Májková, Petra and Zahradová, Lenka and Sandecká, Viera and Adam, Zdeněk and Krejčí, Marta and Kuglík, Petr and Hájek, Roman},
   article_number = {2},
   doi = {https://doi.org/10.3324/haematol.2013.094409},
   keywords = {alpha interferon; bortezomib; lenalidomide; melphalan; thalidomide},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica/the hematology journal},
   title = {Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse},
   volume = {99},
   year = {2014}
}

TY  - JOUR
ID  - 1180892
AU  - Pour, Luděk - Ševčíková, Sabina - Grešliková, Henrieta - Kupská, Renata - Májková, Petra - Zahradová, Lenka - Sandecká, Viera - Adam, Zdeněk - Krejčí, Marta - Kuglík, Petr - Hájek, Roman
PY  - 2014
TI  - Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
JF  - Haematologica/the hematology journal
VL  - 99
IS  - 2
SP  - 360-364
EP  - 360-364
PB  - Fondazione Ferrata Storti
SN  - 03906078
KW  - alpha interferon
KW  - bortezomib
KW  - lenalidomide
KW  - melphalan
KW  - thalidomide
N2  - Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analyzed the prognosis of 226 relapsed multiple myeloma patients treated between 2005 and 2008 and evaluated them for presence of extramedullary relapse. We found evidence of extramedullary relapse in 24% (55 of 226) of relapsed multiple myeloma patients. In 14% (32 of 226) of patients, the lesions were not adjacent to the bone, while extramedullary relapse adjacent to the bone was documented in 10% (23 of 226) of cases. Patients without extramedullary relapse had significantly longer overall survival than patients with extramedullary relapse (109 vs. 38 months; P<0.001). Moreover, patients with soft tissue-related extramedullary relapse had significantly poorer overall survival compared to bone-related extramedullary relapse patients (30 vs. 45 months; P=0.022). Also, overall survival from diagnosis was as low as five months for soft tissue-related extramedullary relapse patients when compared to 12 months overall survival for bone-related extramedullary relapse. This is the first study that shows a significant difference in prognosis for different types of extramedullary relapse. If the extramedullary myeloma infiltration was not bone-related, overall survival after relapse was extremely short (5 months).
ER  -

POUR, Luděk; Sabina ŠEVČÍKOVÁ; Henrieta GREŠLIKOVÁ; Renata KUPSKÁ; Petra MÁJKOVÁ; Lenka ZAHRADOVÁ; Viera SANDECKÁ; Zdeněk ADAM; Marta KREJČÍ; Petr KUGLÍK a Roman HÁJEK. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. \textit{Haematologica/the hematology journal}. Fondazione Ferrata Storti, 2014, roč.~99, č.~2, s.~360-364. ISSN~0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2013.094409.

Přehled o publikaci